Table 1 Baseline characteristics.

From: Muscle and fat composition in patients with newly diagnosed multiple myeloma

 

Median (IQR)

N (%)

Age (years)

65 (59–72)

 

Age > 65 years

 

176 (52)

Age > 70 years

 

108 (32)

Sex (Male)

 

226 (66)

BMI (kg/m2)

28.1 (24.6–31.7)

 

Underweight/Normal/Overweight/Obese (N = 338)

 

2 (1)/90 (27)/126 (37)/120 (36)

ISS III (vs. I/II) (N = 312)

 

86 (28)

R-ISS III (vs. I/II) (N = 280)

 

36 (13)

Laboratory data:

Hb < 10 g/dL (N = 306)

 

78 (25)

Platelets < 150 × 109/L (N = 276)

 

47 (17)

Calcium > 11 mg/dL (N = 300)

 

16 (5)

Creatinine > 2 mg/dL (N = 293)

 

25 (9)

High LDH IU/La (N = 287)

 

37 (13)

BMPCs (%) (N = 310)

40 (20–69)

 

Heavy chain isotype (N = 293)

IgG

 

170 (58)

IgA

 

70 (24)

IgM

 

2 (1)

IgD

 

3 (1)

None

 

48 (16)

Light chain isotype (K/L) (N = 289)

 

200 (69)/89 (31)

ASCT

 

184 (54)

First-line induction (N = 323)

PI

 

109 (34)

IMiD

 

85 (26)

PI+IMiD

 

123 (38)

Other

 

6 (2)

FISH abnormalities

HR IgH translocation (N = 331)

 

50 (15)

Trisomy (any) (N = 329)

 

182 (55)

1q gain (N = 304)

 

86 (28)

MYC abnormality (N = 301)

 

27 (9)

Monosomy 13 (N = 335)

 

137 (41)

Del17p/monosomy 17 (N = 332)

 

48 (14)

  1. aLDH above the laboratory reference range where the test was performed. > 222 IU/L at Mayo Clinic laboratories. Abbreviations: ASCT autologous stem cell transplantation, BMI body mass index, BMPCs bone marrow plasma cells, FISH fluorescence in situ hybridization, IMiD immunomodulatory drug, IQR interquartile range, ISS international staging system, K kappa light chain, L lambda light chain, LDH lactate dehydrogenase, PI proteasome inhibitor, R-ISS revised international staging system.